论文部分内容阅读
目的:探讨分析乌司他丁联合奥曲肽治疗重症急性胰腺炎的临床疗效。方法:以2012年5月到2016年5月期间我院住院治疗的重症急性胰腺炎患者40例,为研究对象,随机分为对照组(20例),在使用奥曲肽的基础上给予患者肠胃减压、抗炎和补液等常规治疗;在常规治疗的基础上,采用乌司他丁联合奥曲肽两种联合治疗的观察组(20例),观察两组治疗效果。结果:观察组用药后痊愈9例,显效4例,有效6例,无效1例,总有效95%。对照组患者用药后,痊愈6例,显效5例,有效5例,无效4例,总有效80%。观察组患者总有效明显高于对照组,差异明显(P<0.05)。结论:乌司他丁联合奥曲肽治疗重症急性胰腺炎具有较好的治疗效果,能够有效减少患者住院时间,减少并发症发生的可能,效果显著,值得推广[1]。
Objective: To investigate the clinical efficacy of ulinastatin combined with octreotide in the treatment of severe acute pancreatitis. Methods: Forty patients with severe acute pancreatitis hospitalized in our hospital from May 2012 to May 2016 were randomly divided into control group (n = 20), patients with gastrointestinal motility Pressure, anti-inflammatory and rehydration routine treatment; on the basis of conventional treatment, ulinastatin combined with octreotide two combination treatment group (20 cases), the two groups were observed. Results: In the observation group, 9 cases recovered after treatment, 4 cases were markedly effective, 6 cases were effective, 1 case was ineffective, and the total effective rate was 95%. Control group patients after treatment, cured 6 cases, 5 cases markedly effective in 5 cases, 4 cases were ineffective, the total effective 80%. The total effective rate in observation group was significantly higher than that in control group, with significant difference (P <0.05). Conclusion: Ulinastatin combined with octreotide in the treatment of severe acute pancreatitis has a good therapeutic effect, which can effectively reduce the length of hospital stay and reduce the possibility of complications. The results are significant and worthy of promotion [1].